Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer [Yahoo! Finan...

Natera, Inc. (NTRA) 
Last natera, inc. earnings: 2/26 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.natera.com
Company Research Source: Yahoo! Finance
AUSTIN, Texas, December 11, 2025 BUSINESS WIRE )--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group (ABCSG), today announced initial translational research results from the international randomized Phase III PALLAS study. Show less Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
NTRA alerts

from News Quantified
Opt-in for
NTRA alerts

from News Quantified